Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy

Br J Haematol. 2023 Jan;200(2):e25-e27. doi: 10.1111/bjh.18540. Epub 2022 Nov 10.

David Gachoud^{1

2}, Claire Bertelli³, Nathalie Rufer^{4

5}

¹ Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
² Medical Education Unit, School of Medicine, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
³ Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁴ Interregional Blood Transfusion SRC, Epalinges, Switzerland.
⁵ Department of Oncology, Lausanne University Hospital and University of Lausanne, Epalinges, Switzerland.

No abstract available

Keywords: COVID-19 convalescent plasma; SARS-CoV-2 viral loads; anti-CD20 therapy; immunocompromised.

Publication types